Literature DB >> 36194373

Diffusion imaging could aid to differentiate between glioma progression and treatment-related abnormalities: a meta-analysis.

Rik van den Elshout1, Tom W J Scheenen1, Chantal M L Driessen2, Robert J Smeenk3, Frederick J A Meijer1, Dylan Henssen4.   

Abstract

BACKGROUND: In a considerable subgroup of glioma patients treated with (chemo) radiation new lesions develop either representing tumor progression (TP) or treatment-related abnormalities (TRA). Quantitative diffusion imaging metrics such as the Apparent Diffusion Coefficient (ADC) and Fractional Anisotropy (FA) have been reported as potential metrics to noninvasively differentiate between these two phenomena. Variability in performance scores of these metrics and absence of a critical overview of the literature contribute to the lack of clinical implementation. This meta-analysis therefore critically reviewed the literature and meta-analyzed the performance scores.
METHODS: Systematic searching was carried out in PubMed, EMBASE and The Cochrane Library. Using predefined criteria, papers were reviewed. Diagnostic accuracy values of suitable papers were meta-analyzed quantitatively.
RESULTS: Of 1252 identified papers, 10 ADC papers, totaling 414 patients, and 4 FA papers, with 154 patients were eligible for meta-analysis. Mean ADC values of the patients in the TP/TRA groups were 1.13 × 10-3mm2/s (95% CI 0.912 × 10-3-1.32 × 10-3mm2/s) and 1.38 × 10-3mm2/s (95% CI 1.33 × 10-3-1.45 × 10-3mm2/s, respectively. Mean FA values of TP/TRA was 0.19 (95% CI 0.189-0.194) and 0.14 (95% CI 0.137-0.143) respectively. A significant mean difference between ADC and FA values in TP versus TRA was observed (p = 0.005).
CONCLUSIONS: Quantitative ADC and FA values could be useful for distinguishing TP from TRA on a meta-level. Further studies using serial imaging of individual patients are warranted to determine the role of diffusion imaging in glioma patients.
© 2022. The Author(s).

Entities:  

Keywords:  Apparent diffusion coefficient; Fractional anisotropy; Glioblastoma; Treatment-related abnormalities; Tumor progression

Year:  2022        PMID: 36194373      PMCID: PMC9532499          DOI: 10.1186/s13244-022-01295-4

Source DB:  PubMed          Journal:  Insights Imaging        ISSN: 1869-4101


  43 in total

1.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

Authors:  Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang
Journal:  J Clin Oncol       Date:  2010-03-15       Impact factor: 44.544

Review 2.  Advanced magnetic resonance imaging techniques to evaluate CNS glioma.

Authors:  Kristina I Olsen; Paul Schroeder; Rod Corby; Ivica Vucic; Dianna M E Bardo
Journal:  Expert Rev Neurother       Date:  2005-11       Impact factor: 4.618

3.  Morphologic MRI features, diffusion tensor imaging and radiation dosimetric analysis to differentiate pseudo-progression from early tumor progression.

Authors:  Ajay Agarwal; Sanath Kumar; Jayant Narang; Lonni Schultz; Tom Mikkelsen; Sumei Wang; Sarmad Siddiqui; Harish Poptani; Rajan Jain
Journal:  J Neurooncol       Date:  2013-02-18       Impact factor: 4.130

4.  Evaluation of absolute and normalized apparent diffusion coefficient (ADC) values within the post-operative T2/FLAIR volume as adverse prognostic indicators in glioblastoma.

Authors:  Andrew Elson; Joseph Bovi; Malika Siker; Chris Schultz; Eric Paulson
Journal:  J Neurooncol       Date:  2015-02-21       Impact factor: 4.130

5.  Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma.

Authors:  W B Pope; A Lai; R Mehta; H J Kim; J Qiao; J R Young; X Xue; J Goldin; M S Brown; P L Nghiemphu; A Tran; T F Cloughesy
Journal:  AJNR Am J Neuroradiol       Date:  2011-02-17       Impact factor: 3.825

6.  Local Fractional Anisotropy Is Reduced in Areas with Tumor Recurrence in Glioblastoma.

Authors:  Stefanie Bette; Thomas Huber; Jens Gempt; Tobias Boeckh-Behrens; Benedikt Wiestler; Victoria Kehl; Florian Ringel; Bernhard Meyer; Claus Zimmer; Jan S Kirschke
Journal:  Radiology       Date:  2016-10-19       Impact factor: 11.105

7.  Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.

Authors:  Francesco Buemi; Giuseppe Guzzardi; Bruno Del Sette; Andrea P Sponghini; Roberta Matheoud; Eleonora Soligo; Alessandra Trisoglio; Alessandro Carriero; Alessandro Stecco
Journal:  Neuroradiol J       Date:  2019-05-08

8.  Diagnostic Accuracy of Centrally Restricted Diffusion in the Differentiation of Treatment-Related Necrosis from Tumor Recurrence in High-Grade Gliomas.

Authors:  N Zakhari; M S Taccone; C Torres; S Chakraborty; J Sinclair; J Woulfe; G H Jansen; T B Nguyen
Journal:  AJNR Am J Neuroradiol       Date:  2017-12-07       Impact factor: 3.825

9.  Pretreatment prediction of brain tumors' response to radiation therapy using high b-value diffusion-weighted MRI.

Authors:  Yael Mardor; Yiftach Roth; Aharon Ochershvilli; Roberto Spiegelmann; Thomas Tichler; Dianne Daniels; Stephan E Maier; Ouzi Nissim; Zvi Ram; Jacob Baram; Arie Orenstein; Raphael Pfeffer
Journal:  Neoplasia       Date:  2004 Mar-Apr       Impact factor: 5.715

10.  Differentiation of pseudoprogression and real progression in glioblastoma using ADC parametric response maps.

Authors:  Caroline Reimer; Katerina Deike; Markus Graf; Peter Reimer; Benedikt Wiestler; Ralf Omar Floca; Philipp Kickingereder; Heinz-Peter Schlemmer; Wolfgang Wick; Martin Bendszus; Alexander Radbruch
Journal:  PLoS One       Date:  2017-04-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.